Ivermectin Nasal Spray for COVID19 Patients

• Status: Not yet recruiting
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The global escalation of COVID19 pandemic has put the health care system under pressure with urgent need for treatment. In the absence of vaccine and approved drug against SARS-COV2 over the past 6 months, the health authorities were obliged to re-purpose existing drugs to fight this pandemic.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Ivermectin

Criteria

Inclusion Criteria:

• mild to moderate severity who are confirmed to be positive for SARS COV 2.

Exclusion Criteria:

• patients with severe form of COVID-19 or those who are on ventilatory support or those with cytokine storm